Featured

The mechanism of action of hydroxyurea in SCD



Published
Andreas E. Kulozik, MD, PhD, Hopp-Children’s Cancer Research Center (KiTZ), University of Heidelberg, Heidelberg, Germany, describes the different mechanisms of action of hydroxyurea in the treatment of sickle cell disease (SCD). Hydroxyurea induces hemoglobin F and affects the adherence of cells to the endothelium of blood vessels, which helps to reduce the incidence of vaso-occlusive crises and other complications of SCD. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Category
Health
Be the first to comment